| Study Period | 2021 - 2032 |
| Market Size in 2025 | USD 2.8 Billion |
| Market Size in 2026 | USD 3.3 Billion |
| Market Size by 2032 | USD 10.1 Billion |
| Projected CAGR | 20.1% |
| Largest Region | North America |
| Fastest-Growing Region | Asia-Pacific |
| Market Structure | Semi-Consolidated |
Explore the market potential with our data-driven report
The metagenomic sequencing market size was USD 2.8 billion for 2025, and it will grow by 20.1% during 2026–2032, to reach USD 10.1 billion by 2032.
This growth is supported by the falling cost of next-generation sequencing, the maturation of shotgun and long-read platforms, and the widening use of culture-independent methods to characterize complex microbial communities directly from clinical, environmental, and agricultural samples. Demand is increasingly anchored in healthcare and public health. Metagenomic next-generation sequencing enables hypothesis-free detection of bacteria, viruses, fungi, and parasites in a single assay, accelerating the diagnosis of infections that evade traditional culture. Peer-reviewed literature indexed in PubMed Central indicates that culture-independent characterization can identify organisms that conventional methods often miss, particularly because many microorganisms cannot be cultured using conventional laboratory techniques. This diagnostic advantage, combined with sustained public investment, is moving the technology from research settings into clinical microbiology, antimicrobial resistance (AMR) surveillance, and microbiome therapeutics development.
Moreover, sustained funding reinforces the market trajectory. For instance, the U.S. National Institutes of Health reports that its Common Fund invested approximately USD 215 million in the Human Microbiome Project. This investment generated reference datasets, microbial genome resources, and computational tools that have advanced microbiome research and supported the development of commercial metagenomics workflows. Bioinformatics pipelines, laboratory automation, and AI-assisted data interpretation are reducing analytical bottlenecks. These advances are making metagenomic sequencing increasingly accessible to research institutions, clinical laboratories, and public health agencies worldwide.
Metagenomic sequencing is transitioning from a research tool into a clinical diagnostic modality, reshaping how and where the technology is deployed. Metagenomic next-generation sequencing (mNGS) enables hypothesis-free detection of bacteria, viruses, fungi, and parasites directly from clinical specimens such as cerebrospinal fluid and blood. This capability facilitates the diagnosis of infections that may be missed by targeted, culture-based testing. This evolution is expanding the use of metagenomic sequencing beyond centralized research laboratories into hospitals, academic medical centers, and reference laboratories. The expanded footprint supports broader implementation in infectious disease diagnostics and more timely treatment decisions. The trend is also driving demand for integrated sequencing services and bioinformatics platforms, as clinical laboratories increasingly require automated data analysis and interpretation rather than raw sequencing outputs.
The U.S. Centers for Disease Control and Prevention (CDC) launched its Next-Generation Sequencing (NGS) Quality Initiative in 2024. The initiative provides quality management tools and standardized practices to improve the reliability, accuracy, and implementation of NGS-based testing across clinical and public health laboratories. As reimbursement pathways and clinical validation frameworks continue to evolve, the adoption of metagenomic sequencing in routine clinical practice is expected to accelerate.
The growing global burden of antimicrobial resistance (AMR) is increasing demand for metagenomic sequencing to strengthen pathogen surveillance, antimicrobial resistance monitoring, and public health preparedness. Metagenomic sequencing enables the direct detection of antimicrobial resistance genes and pathogens from clinical and environmental samples, providing insights into resistance mechanisms, emerging pathogens, and gene dissemination across human, animal, and environmental reservoirs.
A systematic analysis published in The Lancet estimated that bacterial AMR was directly responsible for 1.27 million deaths and associated with 4.95 million deaths worldwide in 2019. This burden establishes AMR as one of the leading global public health threats. This growing burden is driving governments to expand One Health surveillance programs and integrate genomic technologies into national AMR monitoring strategies. The World Health Organization's Global Antimicrobial Resistance and Use Surveillance System (GLASS) continues to expand global participation in standardized AMR surveillance. This expansion strengthens demand for sequencing technologies to monitor resistance patterns, track pathogen evolution, and support evidence-based public health interventions.
Despite favorable demand, the absence of standardized analytical pipelines and a shortage of bioinformatics expertise constrain broader adoption. Metagenomic datasets are large and complex, and converting raw sequence data into actionable conclusions requires specialized expertise, validated reference databases, and computational infrastructure that many laboratories lack, while the persistent gap between falling sequencing costs and the comparatively high cost of downstream data analysis and interpretation limits clinical scalability in low- and middle-income countries.
Inconsistent protocols for sample preparation, sequencing, and bioinformatics analysis also reduce the comparability and reproducibility of results. These inconsistencies slow regulatory acceptance and routine clinical implementation. The World Health Organization (WHO), in its Global Genomic Surveillance Strategy 2022–2032, identified limited bioinformatics capacity, insufficient data-sharing infrastructure, and the lack of standardized analytical frameworks as key barriers to expanding genomic surveillance worldwide.
Emerging applications beyond human diagnostics are creating untapped potential for the metagenomic sequencing market. The expansion of microbiome-based therapeutics, precision nutrition, and agricultural and soil genomics is extending the use of metagenomic sequencing into pharmaceutical research, food systems, and environmental management. Pharmaceutical and biotechnology companies are increasingly exploring uncultured microbial communities to identify novel drug candidates, therapeutic targets, and microbiome-modulating interventions for diseases such as recurrent Clostridioides difficile infection, inflammatory bowel disease (IBD), and cancer. Similarly, agricultural programs are using soil and plant microbiome profiling to improve crop productivity, nutrient-use efficiency, disease resistance, and sustainable farming practices. The growing demand for microbiome research is creating new opportunities for commercial sequencing solutions. For instance, ALS Limited launched a Gut Microbiome Sequencing service, offering researchers a comprehensive end-to-end solution for human and animal gut microbiome analysis.
The U.S. Food and Drug Administration approved the first microbiota-based live biotherapeutic products, Rebyota in 2022 and Vowst in 2023, for the prevention of recurrent Clostridioides difficile infection. This approval demonstrates the growing clinical and commercial potential of microbiome-based therapies. These expanding applications, together with declining sequencing costs and growing reference databases, are creating new commercial opportunities for sequencing platform providers, reagent manufacturers, bioinformatics companies, and sequencing service providers.
The drug discovery category holds the largest market share, of 35%, in 2025. This can be attributed to the increasing research activities in the pharmaceutical and biotechnology industries for novel drug discovery, often as part of collaborations among market players and academic institutes. Around the world, governments and market players are strongly focusing on drug discovery and development, which is why scientists are adopting metagenomic sequencing for accurate and rapid microbial analysis. Many new applications for this type of sequencing, including the genome analysis of microbial populations, have emerged with advances in sequencing technologies. Moreover, metagenomic sequencing enables researchers to access the vast majority of environmental microorganisms that cannot be cultured using conventional laboratory techniques. According to studies published by the U.S. National Center for Biotechnology Information (NCBI), more than 99% of environmental microorganisms are estimated to be unculturable, making metagenomic sequencing an essential tool for discovering novel antibiotics, enzymes, and other bioactive compounds for pharmaceutical research and drug development.
The clinical diagnostics category will have the highest CAGR, of approximately 20.6%, owing to the creation of tools and software for genomic research and rising incidence of infectious diseases. This growth is further supported by the use of mNGS for hypothesis-free pathogen detection, enabling a single assay to identify bacteria, viruses, fungi, and parasites directly from clinical specimens. A review published in MicrobiologyOpen reports that untargeted metagenomic sequencing can identify pathogens in cases where conventional culture or targeted PCR testing fails, improving diagnostic yield and supporting broader adoption in infectious disease diagnostics and clinical microbiology workflows.
The applications analyzed in this report are:
The sequencing category holds the largest market share, of 60%, in 2025, driven by its central role in generating high-quality microbial genomic data for clinical diagnostics, drug discovery, microbiome research, and environmental analysis. Continuous technological advancements have improved sequencing speed, throughput, and cost efficiency, enabling laboratories to process larger sample volumes with greater accuracy and operational efficiency. Reflecting these advancements, in October 2024, Illumina launched the MiSeq i100 Series, a compact benchtop sequencing platform capable of delivering results in approximately four hours, around four times faster than the previous MiSeq system, making high-quality metagenomic sequencing more accessible to smaller research and clinical laboratories.
The data processing & analysis category will have the highest CAGR, driven by the increasing volume and complexity of metagenomic sequencing data generated across clinical diagnostics, microbiome research, environmental monitoring, and drug discovery. As sequencing throughput continues to increase, laboratories require advanced bioinformatics solutions for quality control, taxonomic classification, functional annotation, and antimicrobial resistance gene analysis to convert raw sequencing data into actionable insights. The growing adoption of cloud-based bioinformatics platforms, AI-assisted analytical tools, and automated data interpretation software is enabling laboratories to process large sequencing datasets more efficiently, thereby accelerating demand for data processing and analysis solutions.
The workflows analyzed in this report are:
The shotgun metagenomic sequencing category holds the largest market share in 2025, and it will have the highest CAGR, of approximately 20.8%, owing to the advantages offered by this procedure over other techniques and the surge in the number of genomic-based research activities conducted by academic and research institutes. This method allows for the reading of all the genomes contained within a DNA molecule. For instance, in October 2024, Delve Bio announced a partnership with Broad Clinical Labs to provide clinical metagenomic next-generation sequencing (mNGS) services for infectious disease diagnostics, supporting broader adoption of shotgun metagenomic sequencing in clinical laboratories.
The technologies analyzed in this report are:
The reagents and consumables category holds the largest market share, of 45%, in 2025, driven by the recurring consumption of extraction kits, library-preparation reagents, and sequencing chemistries required for every sequencing run. This category generates recurring, volume-driven revenue that scales directly with sample throughput, unlike one-time instrument purchases. The recurring nature of consumable demand, combined with rising sample volumes across research and clinical applications, sustains this category's leading position.
The services category will have the highest CAGR, driven by growing outsourcing among pharmaceutical, biotechnology, and clinical users who seek end-to-end sequencing and bioinformatics support without building in-house platforms and expertise. Supporting this category, the UK Health Security Agency (UKHSA), through its 2024 Pathogen Genomics Strategy, is advancing the implementation of genomic technologies in routine public health and clinical practice, encouraging broader adoption of sequencing services for pathogen surveillance, antimicrobial resistance monitoring, and infectious disease diagnostics. These initiatives are increasing demand for specialized sequencing and bioinformatics service providers.
The offerings analyzed in this report are:
Drive strategic growth with comprehensive market analysis
North America holds the largest market share, of 40%, in 2025, due to the substantial research and development activities in the pharmaceutical and biotechnology sectors, existence of reputable healthcare businesses, and robust support for the setup of new R&D facilities in the region. Additionally, the earlier adoption of new technologies here than in other regions and the rising prevalence of chronic diseases support this expansion. Moreover, the market is expanding in North America due to the rising use of genomics in genetic research and diagnostics and the accessibility of high research funding and NGS data analysis tools.
Furthermore, government support continues to reinforce the region's leadership in metagenomic sequencing. The U.S. National Institutes of Health (NIH) received an appropriation of approximately USD 47.7 billion for fiscal year 2025, supporting biomedical research across genomics, microbiome science, infectious diseases, and precision medicine. In addition, approximately 82% of the NIH budget is allocated through extramural grants to universities, academic medical centers, and research institutions, accelerating advances in next-generation sequencing (NGS), bioinformatics, and metagenomic research. These sustained investments are strengthening the development and clinical adoption of metagenomic sequencing technologies across North America.
Canada represents a significant market for metagenomic sequencing in North America, supported by developed genomics research ecosystem, government-backed precision medicine initiatives, and collaboration among academic institutions, healthcare organizations, and biotechnology companies. The country is expanding the use of metagenomic sequencing in infectious disease surveillance, microbiome research, and precision medicine while strengthening commercialization of genomics-based technologies.
Additionally, in February 2025, the Government of Canada launched the Canadian Genomics Strategy, committing CAD 175.1 million over seven years (starting in 2024–2025) to accelerate genomics commercialization, improve access to genomic data, and develop a highly skilled workforce. Under the strategy, Genome Canada will receive CAD 96 million through its Genomic Applications Partnership Program (GAPP) to support commercialization and adoption of genomics technologies across healthcare and other sectors.
Asia-Pacific will have the highest CAGR, of approximately 21.0%, driven by the expanding government and private investment in genomics, improving healthcare infrastructure, and increasing research collaborations across developed and emerging economies. Declining sequencing costs and greater accessibility to advanced sequencing platforms are accelerating adoption across clinical diagnostics, agriculture, environmental monitoring, and microbiome research. Large-scale national genomics programs continue to generate sustained demand for sequencing capacity.
Government initiatives are strengthening the regional market, with India expected to be the fastest-growing country in Asia-Pacific, driven by increasing government investment in metagenomic sequencing for infectious disease surveillance and public health preparedness. Under India's National One Health Mission, the Metagenomic Syndromic Surveillance Programme has established four Next-Generation Sequencing (NGS) hubs to strengthen nationwide pathogen surveillance using unbiased metagenomic sequencing. The program integrates clinical syndromic surveillance with metagenomic sequencing for the rapid detection of known, emerging, and novel pathogens, while the designated centers are expected to analyze thousands of samples collected through the national surveillance network. These initiatives are accelerating the adoption of metagenomic sequencing technologies across clinical diagnostics and public health laboratories, supporting the country's rapid market growth.
China held the largest country share within Asia Pacific in 2025, driven by the national precision medicine strategies, government investment in genomics, and one of the world's leading genomics ecosystems. Government-backed infrastructure, including the China National GeneBank (CNGB), has strengthened the country's capabilities in biological resource preservation, large-scale genomic data management, sequencing, and bioinformatics research.
The China National GeneBank, approved and funded by the Chinese government, serves as a national scientific infrastructure for storing, managing, and analyzing large-scale biological and genomic datasets that support precision medicine, biodiversity research, and microbial genomics. Moreover, the China's Precision Medicine Initiative, launched by the central government, carries a planned investment of approximately CNY 60 billion (over USD 9 billion) through 2030 to accelerate genomic research, precision diagnostics, and personalized medicine.
Europe is showing significant growth in the adoption of this technology due to the presence of prominent research institutions and market participants. Additionally, the expansion of the partnerships between government institutions and the providers of sequencing solutions is responsible for the market progress. The region is benefiting from coordinated European initiatives that promote genomics research, microbiome science, and cross-border collaboration. Increasing investment in sequencing infrastructure, standardized genomic data sharing, and precision medicine programs is accelerating the adoption of metagenomic sequencing across clinical diagnostics, infectious disease surveillance, environmental monitoring, and agricultural research. Government-backed funding continues to strengthen this ecosystem.
Under its Choose Europe for Life Sciences strategy, the European Commission announced plans to mobilize up to EUR 100 million through the Horizon Europe 2026–2027 programme to develop One Health microbiome-based solutions. This programme supports research that integrates human, animal, and environmental health.
The regions and countries analysed in this report are:
The market exhibits a semi-consolidated competitive structure, with a limited number of established companies leading the sequencing platform segment while numerous regional and specialized providers compete across reagents, bioinformatics, and sequencing services. High research and development costs, advanced technological requirements, and significant capital investment create substantial barriers to entry for sequencing platform manufacturers, reinforcing the leadership of companies such as Illumina, Thermo Fisher Scientific, Oxford Nanopore Technologies, and Pacific Biosciences. At the same time, companies including QIAGEN, BGI Genomics, Eurofins Scientific, and Macrogen compete by expanding sequencing services, sample preparation, reagents, and bioinformatics capabilities. Additionally, competition is increasingly driven by technological innovation, strategic collaborations, workflow integration, and the development of end-to-end sequencing solutions that combine instruments, consumables, software, and data analysis services, strengthening customer retention and recurring revenue opportunities.
Want a report tailored exactly to your business need?
Request CustomizationLeading companies across industries trust us to deliver data-driven insights and innovative solutions for their most critical decisions. From data-driven strategies to actionable insights, we empower the decision-makers who shape industries and define the future. From Fortune 500 companies to innovative startups, we are proud to partner with organisations that drive progress in their industries.
Working with P&S Intelligence and their team was an absolute pleasure – their awareness of timelines and commitment to value greatly contributed to our project's success. Eagerly anticipating future collaborations.
McKinsey & Company
India
Our insights into the minutest levels of the markets, including the latest trends and competitive landscape, give you all the answers you need to take your business to new heights
We take a cautious approach to protecting your personal and confidential information. Trust is the strongest bond that connects us and our clients, and trust we build by complying with all international and domestic data protection and privacy laws
Customize the Report to Align with Your Business Objectives
Request the Free Sample Pages